Translate the text from English to Welsh.



 
Welsh Government officials were notified yesterday (7 October) that there may be a possible UK\-wide supply problem affecting the provision of diagnostic kits and reagents supplied by the pharmaceutical company Roche.


Roche are the main UK supplier of a number of test kits in laboratory medicine, including; bio chemistry, immunohistochemistry tests, and COVID\-19 tests. Inability to process certain diagnostic tests in a timely way could have an impact on clinical decision making, affecting the way we can provide services within NHS Wales.


Officials across the UK held a call with Roche representatives, where it was confirmed that Roche are experiencing both logistical and technical problems following relocation of their main distribution centre.  This has resulted in Roche not being able to meet order demand subsequently developing a backlog.


Roche have confirmed that they implementing a recovery plan to provide reassurance that the impact on the NHS across the UK is being managed and minimised as far as possible. In particular, Roche have given assurance that the COVID testing programme and Blood Services will be prioritised to ensure that they have sufficient supply to maintain full operation. 


Welsh Government officials will continue to work with their counterparts across the UK and Roche until this matter is resolved. 


I have asked officials to put in place a national response in collaboration with NHS Wales colleagues to ensure that any impact on the NHS in Wales in minimised.  I will be receiving regular updates and will update Members in due course.







Translation:


 
Cafodd swyddogion Llywodraeth Cymru wybod ddoe (7 Hydref) fod problem gyflenwi bosibl ledled y DU sy'n effeithio ar y gwaith o ddarparu’r pecynnau a’r adweithredyddion diagnostig a gyflenwir gan gwmni fferyllol Roche. 


Roche yw prif gyflenwr nifer o’r pecynnau profi a ddefnyddir mewn meddygaeth labordy yn y DU, gan gynnwys profion biocemeg, profion imiwnohistocemeg a phrofion COVID\-19\. Gallai diffyg gallu i brosesu rhai profion diagnostig mewn modd amserol effeithio ar y broses o wneud penderfyniadau clinigol, a thrwy hynny effeithio ar y modd yr ydym yn gallu darparu gwasanaethau o fewn GIG Cymru.


Mae galwad wedi’i chynnal rhwng swyddogion ledled y DU a chynrychiolwyr Roche, a chafwyd cadarnhad fod Roche yn cael problemau logistaidd a thechnegol ar ôl adleoli eu prif ganolfan ddosbarthu.  Mae hyn yn golygu nad yw Roche wedi gallu ateb y galw am gyflenwadau, ac felly bod archebion yn cronni.


Mae Roche wedi cadarnhau bod ganddynt gynllun adfer ar waith i sicrhau bod yr effaith ar y GIG ledled y Deyrnas Unedig yn cael ei rheoli a'i lleihau cyn belled ag y bo modd. Yn benodol, mae Roche wedi rhoi sicrwydd y bydd rhaglen brofi COVID a'r Gwasanaethau Gwaed yn cael blaenoriaeth er mwyn sicrhau bod ganddynt ddigon o gyflenwadau i gynnal eu gwaith yn llawn.


Bydd swyddogion Llywodraeth Cymru yn parhau i weithio gyda'u cymheiriaid ledled y DU a chyda Roche hyd nes y caiff y mater hwn ei ddatrys.   


Rwyf wedi gofyn i swyddogion roi ymateb cenedlaethol ar waith mewn cydweithrediad â chydweithwyr yn GIG Cymru i sicrhau bod cyn lleied o effaith â phosibl ar y Gwasanaeth Iechyd yng Nghymru.  Byddaf yn cael yr wybodaeth ddiweddaraf yn rheolaidd ac yn rhoi diweddariad i’r Aelodau maes o law.